HOME >> BIOLOGY >> NEWS
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The data are part of a presentation at the annual meeting of European League Against Rheumatism being held this week in Lisbon, Portugal.

"A significant number of patients treated with ENBREL in this study saw a marked improvement in as early as two weeks after initiation of treatment. Patients reached maximum relief within the first two months of the study and experienced sustained results for the remainder of the six-month study," said Dr. John Davis, assistant professor of medicine at the University of California-San Francisco and associate director of the Department of Medicine Clinical Trials Center. "I am excited about these encouraging results with ENBREL, especially since it is the first treatment to show improvement in AS patients' range of spinal motion in a phase 3 study."

The multi-center, double-blind, placebo-controlled study randomized 277 patients to receive either ENBREL (25 mg twice weekly; n=138) or placebo (n=139) over a 6-month period. The primary endpoint of the pivotal Phase 3 study was the percentage of patients at 12 weeks and 24 weeks achieving a 20 percent improvement in the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20), a composite measure that includes back pain, inflammation and physical function.

At week 12, 60 percent of patients treated with ENBREL achieved the ASAS 20 compared with 27 percent of patients in the placebo group. At 24 weeks, 58 percent of patients treated with ENBREL achieved the ASAS 20 compared with 23 percent of the placebo pati
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
(Date:7/28/2014)... a new study suggest two ways to effectively address the ... in obese women, compared to women of a normal body ... researchers say, but as the population has increased in weight, ... obese women. Studies have consistently found that obesity has a ... in turn affect how well the pill prevents pregnancy. ...
(Date:7/28/2014)... Children,s Research Hospital study found that 73 percent of ... risk of developing metabolic syndrome and related health problems ... appear in the current issue of the journal ... adult survivors of childhood cancer in the study had ... like high blood pressure, abdominal obesity, elevated triglyceride and ...
(Date:7/28/2014)... A powerful new tool that can help advance ... green and renewable bioenergy, has been developed by ... Joint BioEnergy Institute (JBEI), a multi-institutional partnership led ... JBEI researchers have developed an assay that enables ... nucleotide sugar transporters, critical components in the biosynthesis ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3How sweet it is 2How sweet it is 3
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in ... a new leadership appointment designed to drive the company’s ... , Maik Jornitz, Chief Operating Officer of G-Con ... with leading the pioneering company through its next phase ... of development and look forward to providing our next ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The first ... a next generation approach to robotics. What sets Droidles ... patent pending technology that allows them to communicate, share ... wirelessly over the internet. , “The invention is the ... the little Droidles a life of their own, both ...
(Date:7/29/2014)... July 29, 2014 Eppendorf Centrifuge ... product selection. Eppendorf 5427 R is geared towards high-end ... – it is targeted towards work requiring high sample ... R as it compliments their extensive 16, 48, and ... of microcentrifuge tubes, PCR tubes, PCR strip tubes, and ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The prestigious ... of Congress was recently awarded to Juliana Hillis and ... MA, for their project, “From an Egg, Everything: America’s ... 3,000 final entries for the National History Day program ... 300 historians and educators in Washington, D.C. , The ...
Breaking Biology Technology:G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Droidles, the Social Network of Robots and Open Source Platform for the Internet of Things, Launches for Crowd Funding on IndieGoGo.com 2International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
Cached News: